A Study of [14C]-LY4064809 in Healthy Participants
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Basic science
Enrollment
7actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-27 | actual | When the study began enrolling |
| Primary completion | 2026-05-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-26 | actual | The whole study's end, after follow-up |
| First posted | 2026-04-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: LY4064809
- Drug: [14C]-LY4064809
Primary outcome
what the primary-completion date above is the date OFTo determine the absolute bioavailability (F) of LY4064809 following administration of a single oral dose compared to an intravenous reference dose in healthy participants.
measured Baseline up to Day 14
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed